Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Change in Receivables (2017 - 2024)

Avalo Therapeutics' Change in Receivables history spans 8 years, with the latest figure at -$387000.0 for Q4 2024.

  • For Q4 2024, Change in Receivables rose 72.4% year-over-year to -$387000.0; the TTM value through Dec 2024 reached $475000.0, up 126.64%, while the annual FY2024 figure was $475000.0, 126.64% up from the prior year.
  • Change in Receivables reached -$387000.0 in Q4 2024 per AVTX's latest filing, down from $862000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $3.7 million in Q3 2020 to a low of -$2.3 million in Q1 2022.
  • Average Change in Receivables over 5 years is -$106900.0, with a median of -$145500.0 recorded in 2021.
  • Peak YoY movement for Change in Receivables: soared 5501.83% in 2020, then crashed 5337.5% in 2023.
  • A 5-year view of Change in Receivables shows it stood at -$2.1 million in 2020, then soared by 33.27% to -$1.4 million in 2021, then skyrocketed by 143.65% to $605000.0 in 2022, then crashed by 331.74% to -$1.4 million in 2023, then surged by 72.4% to -$387000.0 in 2024.
  • Per Business Quant, the three most recent readings for AVTX's Change in Receivables are -$387000.0 (Q4 2024), $862000.0 (Q3 2024), and $101000.0 (Q2 2024).